Artificial Intelligence for Alzheimer’s Disease Diagnosis
Bringing World-Class AI Risk Prediction and Decision Support to:
• Physicians:
Providing timely insights for physicians serving communities without access to complex diagnostic infrastructure.
• Researchers:
Multimodal data analysis to identify potential risk factors and better understand disease progression.
0
Patent
Applications
0
Research
Challenge Entries
0
Published
Abstracts
Our team harnesses the power of artificial intelligence to drive meaningful progress in understanding complex neurological diseases like Alzheimer’s. We design AI models that transform diverse clinical and research data into insights, helping reveal patterns and signals that might otherwise stay hidden.
AI Innovation for
Alzheimer’s Research
At the AlzInsights Summit 2, hosted by the Alzheimer’s Disease Data Initiative, IGC Pharma presented a live demonstration of aha™: the Agentic Harmonization Assistant—an AI initiative exploring how diverse Alzheimer’s datasets can be harmonized to support research insights. Recognized as a semifinalist in the AlzInsights AI Prize, aha™ reflects IGC.
Pharma’s commitment to advancing scalable, data-driven innovation that may help accelerate progress in Alzheimer’s research.
Empowering Better Outcomes Through
Data-Driven Alzheimer’s Solutions
Reduce Diagnostic Uncertainty
Evidence You Can Trust: Interpretable, science-backed outputs with clarity around uncertainty.
Smart Recommendations, Personalized Insights
Helping reach underserved communities with efficient diagnostic support without requiring advanced infrastructure.
Integrate Effortlessly
Multidimensional data analysis helps uncover potential risk factors, revealing complex combinations of social, genetic, and lifestyle determinants.
Reduce inequality
Designed to improve diagnostic accuracy in settings where false negatives are common.
aha™: Agentic
Harmonization Assistant
High-quality prediction starts with high-quality data. aha™ automatically harmonizes clinical, imaging, sociodemographic, and molecular datasets for Alzheimer’s disease, transforming heterogeneous cohorts into a single, trustworthy dataset ready for advanced analytics and AI models.
Discover MINT-AD™
MINT-AD™ leverages decades of international research in aging, genomics, clinical practice, and cognitive science to support AI-driven clinical decision making in Alzheimer’s disease.
Other projects you may like
Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout
